Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Masitinib plus FOLFIRI vs placebo plus FOLFIRI as second-line therapy in metastatic colorectal cancer
CTR20150854Phase 3Active
- Sponsor
- AB Science
- Start
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of masitinib in metastatic colon cancer (mCRC), sponsored by AB Science. Started May 2016; status: active.
02
Drugs
masitinib
03
Conditions
metastatic colon cancer (mCRC)
Beyond the preview
Go deeper on CTR20150854.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20150854.